KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer (Q27852101)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer	scientific article

Statements

scholarly article

1 reference

13 November 2016

KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer (English)

1 reference

13 November 2016

pancreatic cancer

1 reference

based on heuristic

inferred from title

author name string

Stefan Boeck

1

0 references

Andreas Jung

2

0 references

Rüdiger P Laubender

3

0 references

Jens Neumann

4

0 references

Rosalind Egg

5

0 references

Clara Goritschan

6

0 references

Steffen Ormanns

7

0 references

Michael Haas

8

0 references

Dominik P Modest

9

0 references

Thomas Kirchner

10

0 references

Volker Heinemann

11

0 references

publication date

April 2013

0 references

Journal of Gastroenterology

0 references

48

0 references

544-8

0 references

4

0 references

Systemic treatment of advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0767-4

21 January 2018

Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0767-4

21 January 2018

Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0767-4

21 January 2018

Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0767-4

21 January 2018

EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0767-4

21 January 2018

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0767-4

21 January 2018

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0767-4

21 January 2018

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0767-4

21 January 2018

Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0767-4

21 January 2018

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0767-4

21 January 2018

Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0767-4

21 January 2018

Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK01

1 reference

https://pubmed.ncbi.nlm.nih.gov/23435671

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23435671

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00535-013-0767-4

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

release_4e7lkeq3ife6pmuyyshahhahh4

1 reference

https://api.fatcat.wiki/v0/release/4e7lkeq3ife6pmuyyshahhahh4

24 November 2022

based on heuristic

mapped directly with Wikidata item

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27852101&oldid=1843535763"